IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Apyx Medical Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Apyx Medical Corporation (“Apyx” or “the Company”) (NASDAQ: APYX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between August 1, 2018 and April 1, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before June 17, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. The clinical study of Apyx’s J-Plasma for dermal resurfacing did not reach its primary efficacy endpoint. The study did not support the Company’s application for regulatory clearance. In fact, Apyx was unlikely to receive approval for the use of J-Plasma in dermal resurfacing. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Apyx, investors suffered damages.